Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Top Stages
https://app.dealroom.co/companies/***
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Visen Pharmaceuticals
Series A in 2018
Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.
Complex Biosystems
Acquisition in 2007
Complex Biosystems develops drugs for therapeutic profiling of macromolecules. Focuses on in-vitro and in-vivo performance of formulation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.